ZA988232B - Aromatic C16-C20-substituted tetrahydro prostaglandins useful as FP agonists - Google Patents

Aromatic C16-C20-substituted tetrahydro prostaglandins useful as FP agonists

Info

Publication number
ZA988232B
ZA988232B ZA988232A ZA988232A ZA988232B ZA 988232 B ZA988232 B ZA 988232B ZA 988232 A ZA988232 A ZA 988232A ZA 988232 A ZA988232 A ZA 988232A ZA 988232 B ZA988232 B ZA 988232B
Authority
ZA
South Africa
Prior art keywords
agonists
aromatic
substituted tetrahydro
prostaglandins useful
tetrahydro prostaglandins
Prior art date
Application number
ZA988232A
Other languages
English (en)
Inventor
Mitchell Anthony Delong
Jack S Amburgey Jr
Haiyan George Daio
John August Wos
De Biswananth
David Lindsey Soper
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of ZA988232B publication Critical patent/ZA988232B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0041—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA988232A 1997-09-09 1998-09-09 Aromatic C16-C20-substituted tetrahydro prostaglandins useful as FP agonists ZA988232B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5825297P 1997-09-09 1997-09-09

Publications (1)

Publication Number Publication Date
ZA988232B true ZA988232B (en) 1999-03-09

Family

ID=22015635

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA988232A ZA988232B (en) 1997-09-09 1998-09-09 Aromatic C16-C20-substituted tetrahydro prostaglandins useful as FP agonists

Country Status (24)

Country Link
US (1) US6048895A (sk)
EP (1) EP1012137B1 (sk)
JP (2) JP4619531B2 (sk)
KR (1) KR20010023838A (sk)
CN (1) CN1269784A (sk)
AR (1) AR017078A1 (sk)
AT (1) ATE227266T1 (sk)
AU (1) AU731032B2 (sk)
BR (1) BR9812631A (sk)
CA (1) CA2303801C (sk)
CO (1) CO4970733A1 (sk)
DE (1) DE69809268T2 (sk)
DK (1) DK1012137T3 (sk)
HU (1) HUP0004427A3 (sk)
ID (1) ID24845A (sk)
IL (1) IL134840A0 (sk)
NO (1) NO20001139L (sk)
NZ (1) NZ503738A (sk)
PE (1) PE123099A1 (sk)
PL (1) PL339221A1 (sk)
SK (1) SK3382000A3 (sk)
TR (1) TR200000673T2 (sk)
WO (1) WO1999012898A1 (sk)
ZA (1) ZA988232B (sk)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69714274T3 (de) * 1996-09-17 2006-06-01 Asahi Glass Co., Ltd. Fluorierte prostaglandinderivate und medikamente
JP4619531B2 (ja) * 1997-09-09 2011-01-26 デューク ユニバーシティ Ｆｐアゴニストとして有用な、芳香族のあるｃ１６〜ｃ２０が置換されたテトラヒドロプロスタグランジン類
EP1159266B1 (en) * 1999-03-05 2004-11-03 Duke University C-16 unsaturated fp-selective prostaglandins analogs
DE60003435T2 (de) * 1999-08-04 2004-05-19 The Procter & Gamble Company, Cincinnati Neue 2-decarboxy-2-phosphinico prostaglandin f analoge
US20020013294A1 (en) * 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020037914A1 (en) * 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020172693A1 (en) * 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020146439A1 (en) * 2000-03-31 2002-10-10 Delong Mitchell Anthony Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins
KR100437873B1 (ko) * 2001-05-08 2004-06-26 연성정밀화학(주) 프로스타글란딘 유도체의 제조방법 및 그의 입체특이적출발물질
US6905827B2 (en) * 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
EP1812017A2 (en) * 2004-10-21 2007-08-01 Duke University Ophthamological drugs
US20070254920A1 (en) * 2006-04-26 2007-11-01 Aerie Pharmaceuticals, Inc. Prodrug derivatives of acids using alcohols with homotopic hydroxy groups and methods for their preparation and use
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
MX2010004834A (es) 2007-10-31 2010-10-20 Pamela Lipkin Composiciones de analogos de prostaglandina y metodos para tratar las condiciones relacionadas al epitelio.
WO2010039535A1 (en) * 2008-09-23 2010-04-08 Meta Cosmetics, Llc Compositions and methods to treat epithelial-related conditions
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
CA2739571A1 (en) 2008-10-29 2010-08-26 Aerie Pharmaceuticals, Inc. Amino acid salts of prostaglandins
US8722739B2 (en) 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8623918B2 (en) * 2008-10-29 2014-01-07 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US20110293549A1 (en) 2009-02-03 2011-12-01 Athena Cosmetics, Inc. Composition, method and kit for enhancing hair
EP3354643B1 (en) 2009-05-01 2020-10-28 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
CN103864653A (zh) * 2012-12-10 2014-06-18 韩冰 一类降低眼压的化合物及其用途
EP3461484B9 (en) 2013-03-15 2021-06-09 Aerie Pharmaceuticals, Inc. Dimesylate salts of 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl, their combinations with prostaglandins and the use thereof in the treatment of ocular disorders
US9643927B1 (en) 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
MX2019002396A (es) 2016-08-31 2019-07-08 Aerie Pharmaceuticals Inc Composiciones oftalmicas.
EP3609871A4 (en) 2017-03-31 2021-01-06 Aerie Pharmaceuticals, Inc. ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS
AU2019337703B2 (en) 2018-09-14 2023-02-02 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3776938A (en) * 1958-05-28 1973-12-04 S Bergstrom Dihydro-pge1
US4011262A (en) * 1972-07-13 1977-03-08 Pfizer Inc. 13,14-Dihydro-15-substituted-ω-pentanorprostaglandins of the two series
DD118856A5 (sk) * 1972-11-08 1976-03-20
US4024179A (en) * 1972-11-08 1977-05-17 Pfizer Inc. Substituted ω-pentanorprostaglandins
IL50310A (en) * 1972-11-08 1977-08-31 Pfizer Dimethyl ketophosphonates
JPS5720305B2 (sk) * 1973-02-28 1982-04-27
DE2365101A1 (de) * 1973-12-21 1975-07-10 Schering Ag Neue prostansaeurederivate und verfahren zu ihrer herstellung
DE2460990A1 (de) * 1974-12-21 1976-07-01 Hoechst Ag Neue prostaglandin-analoga und verfahren zu ihrer herstellung
GB1507211A (en) * 1975-02-14 1978-04-12 Ono Pharmaceutical Co Prostaglandin analogues
GB1506817A (en) * 1975-03-31 1978-04-12 Upjohn Co Prostaglandins
DE2517771A1 (de) * 1975-04-18 1976-10-28 Schering Ag Neue prostaglandin-acetylen-analoga und verfahren zu ihrer herstellung
US4051238A (en) * 1976-06-03 1977-09-27 The Upjohn Company Treatment of genital tract diseases of domestic animals with prostaglandins
DE2737808A1 (de) * 1976-08-27 1978-03-16 Pfizer 2-substituierte aryl-heterocyclische omega-pentanorprostaglandine
US4206151A (en) * 1978-12-21 1980-06-03 American Cyanamid Company 15-Deoxy-16-hydroxy-16-vinyl or cyclopropyl prostan-1-ols of the E, A and F series
JPS5829710A (ja) * 1981-03-25 1983-02-22 ジ・アツプジヨン・カンパニ− Ｐｇ類による骨孔症の治療
US4621100A (en) * 1981-09-25 1986-11-04 The Upjohn Company Treatment of osteoporosis with prostaglandins
CA1324129C (en) * 1987-04-30 1993-11-09 Ryuzo Ueno Prostaglandins of the f series
US5166178B1 (en) * 1987-09-18 1998-07-21 R Tech Ueno Ltd Ocular hypotensive agents
US5321128A (en) * 1988-09-06 1994-06-14 Kabi Pharmacia Ab Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
ES2317964T5 (es) * 1988-09-06 2015-02-20 Pfizer Health Ab Derivado de prostaglandina-F2alfa para el tratamiento de glaucoma o hipertensión ocular
US5296504A (en) * 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
CA2030345C (en) * 1989-11-22 1998-12-08 Ryuji Ueno Use of 15-keto-prostaglandin compound for improvement of encephalic function
TW224942B (sk) * 1990-04-04 1994-06-11 Adka Ueno Kk
US5302617A (en) * 1990-04-27 1994-04-12 Kabushikikaisha Ueno Seiyaku Oyo Kenkyuio Biochemical treatment with 15-dehydroxy-16-oxoprostaglandin compounds
DE4024347A1 (de) * 1990-07-27 1992-01-30 Schering Ag Cyclopentanderivate, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung
US5409911A (en) * 1992-09-11 1995-04-25 Merck & Co., Inc. Prostaglandin analog for treating osteoporosis
US5688819A (en) * 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5834498A (en) * 1992-09-21 1998-11-10 Allergan Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5332730A (en) * 1992-10-16 1994-07-26 Allergan, Inc. Azido derivatives of cyclopentane heptanoic or heptenoic acid
AU665287B2 (en) * 1992-12-21 1995-12-21 Alcon Laboratories, Inc. Prostaglandin combinations in glaucoma therapy
US5510383A (en) * 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
US5545665A (en) * 1993-12-28 1996-08-13 Allergan Cyclopentane(ene) heptenoic or heptanoic acids and derivatives thereof useful as therapeutic agents
WO1998021180A1 (en) * 1995-06-07 1998-05-22 Alcon Laboratories, Inc. Conformationally rigid aryl- or heteroaryl prostaglandins for use in glaucoma therapy
WO1997023225A1 (en) * 1995-12-22 1997-07-03 Alcon Laboratories, Inc. Combinations of dp and fp type prostaglandins for lowering iop
US5703108A (en) * 1996-02-28 1997-12-30 Pfizer Inc. Bone deposition by certain prostaglandin agonists
US5741810A (en) * 1996-02-29 1998-04-21 Allergan Cyclopentane heptan(ene)oic acid, 2- heteroarylalkenyl derivatives as therapeutic agents
JP3187438B2 (ja) * 1996-06-10 2001-07-11 株式会社アールテック・ウエノ エンドセリン拮抗剤
DE69714274T3 (de) * 1996-09-17 2006-06-01 Asahi Glass Co., Ltd. Fluorierte prostaglandinderivate und medikamente
WO1998020880A2 (en) * 1996-11-12 1998-05-22 Alcon Laboratories, Inc. 11-halo prostaglandins for the treatment of glaucoma or ocular hypertension
WO1998020881A1 (en) * 1996-11-12 1998-05-22 Alcon Laboratories, Inc 15-ketal prostaglandins for the treatment of glaucoma or ocular hypertension
EP1007028A4 (en) * 1997-05-09 2002-06-05 TREATING GLAUCOMA WITH 8 ISO PROSTAGLANDINE
JP4619531B2 (ja) * 1997-09-09 2011-01-26 デューク ユニバーシティ Ｆｐアゴニストとして有用な、芳香族のあるｃ１６〜ｃ２０が置換されたテトラヒドロプロスタグランジン類

Also Published As

Publication number Publication date
KR20010023838A (ko) 2001-03-26
PE123099A1 (es) 2000-02-02
CA2303801A1 (en) 1999-03-18
JP5330324B2 (ja) 2013-10-30
EP1012137B1 (en) 2002-11-06
JP4619531B2 (ja) 2011-01-26
JP2001515885A (ja) 2001-09-25
HUP0004427A3 (en) 2001-09-28
AU731032B2 (en) 2001-03-22
ATE227266T1 (de) 2002-11-15
ID24845A (id) 2000-08-24
EP1012137A1 (en) 2000-06-28
TR200000673T2 (tr) 2000-11-21
NZ503738A (en) 2001-05-25
AR017078A1 (es) 2001-08-22
WO1999012898A1 (en) 1999-03-18
AU9224098A (en) 1999-03-29
BR9812631A (pt) 2000-08-22
SK3382000A3 (en) 2000-10-09
CA2303801C (en) 2005-05-10
DE69809268T2 (de) 2003-08-28
CO4970733A1 (es) 2000-11-07
US6048895A (en) 2000-04-11
IL134840A0 (en) 2001-05-20
PL339221A1 (en) 2000-12-04
JP2010254705A (ja) 2010-11-11
NO20001139D0 (no) 2000-03-06
CN1269784A (zh) 2000-10-11
HUP0004427A2 (hu) 2001-05-28
NO20001139L (no) 2000-05-04
DE69809268D1 (de) 2002-12-12
DK1012137T3 (da) 2003-03-10

Similar Documents

Publication Publication Date Title
ZA988230B (en) Aromatic C16-C20-substituted tetrahydro prostaglandins useful as FP agonists
ZA988232B (en) Aromatic C16-C20-substituted tetrahydro prostaglandins useful as FP agonists
ZA988231B (en) Aromatic C16-C20-substituted tetrahydro prostaglandins useful as FP agonists
AP9801356A0 (en) Prostaglandin agonists
DE69941083D1 (en) 12,13-cyclopropan-epothilonderivate
ZA989537B (en) Lubricating composition
GB2345916B (en) Alkaline solid block composition
ZA986588B (en) Substituted 1,2,3,4-tetrahydronaphthalene derivatives
ZA974359B (en) Microencapsulated compositions.
PL339219A1 (en) Substituted 2-pyrolydinones as pkc activators
ZA9811502B (en) Novel composition.
PL338017A1 (en) Novel composition
EP0958806A4 (en) HAIR COLORING COMPOSITION
ZA200006118B (en) Novel composition.
GB9800912D0 (en) New composition
GB9701031D0 (en) Composition
ZA9710576B (en) 2-imidazolinylaminoindazole compounds useful as alpha-2-adrenoceptor agonists
ZA200000192B (en) Novel composition.
GB9801583D0 (en) Anti-snore gargle composition
ZA981739B (en) Composition.
EG23068A (en) Pesticidale composition
ZA991829B (en) Novel composition.
GB9611276D0 (en) Self indicating composition
GB9813561D0 (en) Novel composition
GB9806685D0 (en) Novel composition